Top

Published in:

01-10-2012 | Pathogenesis of Type 1 Diabetes (AG Ziegler, Section Editor)

The Role of Hyaluronan and the Extracellular Matrix in Islet Inflammation and Immune Regulation

Authors: Paul L. Bollyky, Marika Bogdani, Jennifer B. Bollyky, Rebecca L. Hull, Thomas N. Wight

Published in: Current Diabetes Reports | Issue 5/2012

Abstract

Type 1 diabetes (T1D) is a disease that in most individuals results from autoimmune attack of a single tissue type, the pancreatic islet. A fundamental, unanswered question in T1D pathogenesis is how the islet tissue environment influences immune regulation. This crosstalk is likely to be communicated through the extracellular matrix (ECM). Here, we review what is known about the ECM in insulitis and examine how the tissue environment is synchronized with immune regulation. In particular, we focus on the role of hyaluronan (HA) and its interactions with Foxp3+ regulatory T-cells (Treg). We propose that HA is a “keystone molecule” in the inflammatory milieu and that HA, together with its associated binding proteins and receptors, is an appropriate point of entry for investigations into how ECM influences immune regulation in the islet.

Andre I, Gonzalez A, Wang B, Katz J, Benoist C, Mathis D. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci U S A. 1996;3:2260–3.CrossRef

Capitan JA, Cuesta JA. Species assembly in model ecosystems, I: analysis of the population model and the invasion dynamics. J Theor Biol. 2011;269:330–43.PubMedCrossRef

Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol. 2007;23:435–61.PubMedCrossRef

Day AJ, Prestwich GD. Hyaluronan-binding proteins: tying up the giant. J Biol Chem. 2002;277:4585–8.PubMedCrossRef

Edelstam GA, Laurent UB, Lundkvist OE, Fraser JR, Laurent TC. Concentration and turnover of intraperitoneal hyaluronan during inflammation. Inflammation. 1992;16:459–69.PubMedCrossRef

Laurent TC, Fraser JR. Hyaluronan. FASEB J. 1992;6:2397–404.PubMed

Denis MC, Mahmood U, Benoist C, Mathis D, Weissleder R. Imaging inflammation of the pancreatic islets in type 1 diabetes. Proc Natl Acad Sci U S A. 2004;101:12634–9.PubMedCrossRef

Stern R, Jedrzejas MJ. Hyaluronidases. their genomics, structures, and mechanisms of action. Chem Rev. 2006;106:818–39.PubMedCrossRef

Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. Eur J Cell Biol. 2006;85:699–715.PubMedCrossRef

10.

•• Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev. 2011;91:221–64. This review is a comprehensive and accessible resource for anyone interested in hyaluronan studies. PubMedCrossRef

11.

Hull RL, Johnson PY, Braun KR, Day AJ, Wight TN. Hyaluronan and hyaluronan binding proteins are normal components of mouse pancreatic islets and are differentially expressed by islet endocrine cell types. J Histochem Cytochem. 2012;in press.

12.

Powell JD, Horton MR. Threat matrix. Low-molecular-weight hyaluronan (HA) as a danger signal. Immunol Res. 2005;31:207–18.PubMedCrossRef

13.

Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2012;4:a006049.PubMedCrossRef

14.

Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med. 2002;195:99–111.PubMedCrossRef

15.

Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005;11:1173–9.PubMedCrossRef

16.

Tesar BM, Jiang D, Liang J, Palmer SM, Noble PW, Goldstein DR. The role of hyaluronan degradation products as innate alloimmune agonists. Am J Transplant. 2006;6:2622–35.PubMedCrossRef

17.

Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, Horton MR. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol. 2006;177:1272–81.PubMed

18.

del Fresco C, Otero K, Gomez-Garcia L, Gonzalez-Leon MC, Soler-Ranger L, Fuentes-Prior P, et al. Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol. 2005;174:3032–40.

19.

Teder P, Vandivier RW, Jiang D, Liang J, Cohn L, Pure E, et al. Resolution of lung inflammation by CD44. Science. 2002;296:155–8.PubMedCrossRef

20.

Bollyky PL, Bice JB, Sweet IR, Falk BA, Gebe JA, Clark AE, et al. The toll-like receptor signaling molecule Myd88 contributes to pancreatic β-cell homeostasis in response to injury. PLoS One. 2009;4:e5063.PubMedCrossRef

21.

Gao F, Yang CX, Mo W, Liu YW, He YQ. Hyaluronan oligosaccharides are potential stimulators to angiogenesis via RHAMM mediated signal pathway in wound healing. Clin Invest Med. 2008;31:E106–16.PubMed

22.

Wei L, Xiong H, Li B, Gong Z, Li J, Cai H, et al. Change of HA molecular size and boundary lubrication in synovial fluid of patients with temporomandibular disorders. J Oral Rehabil. 2010;37:271–7.PubMedCrossRef

23.

• Liang J, Jiang D, Jung Y, Xie T, Ingram J, Church T, et al. Role of hyaluronan and hyaluronan‐binding proteins in human asthma. J Allergy Clin Immunol. 2011;128:403–11. These studies are a good introduction into how HA size and HA binding partners can influence inflammation.

24.

Mummert ME. Immunologic roles of hyaluronan. Immunol Res. 2005;31:189–206.PubMedCrossRef

25.

Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 2006;20:9–22.PubMedCrossRef

26.

Termeer C, Sleeman JP, Simon JC. Hyaluronan–magic glue for the regulation of the immune response? Trends Immunol. 2003;24:112–4.PubMedCrossRef

27.

Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev. 2011;1:221–64.CrossRef

28.

Campo GM, Avenoso A, Nastasi G, Micali A, Prestipino V, Vaccaro M, et al. Hyaluronan reduces inflammation in experimental arthritis by modulating TLR-2 and TLR-4 cartilage expression. Biochim Biophys Acta. 2011;1812:1170–81.PubMedCrossRef

29.

• Nagy N, Freudenberger T, Melchior-Becker A, Rock K, Ter BM, Jastrow H, et al. Inhibition of hyaluronan synthesis accelerates murine atherosclerosis: novel insights into the role of hyaluronan synthesis. Circulation. 2010;122:2313–22. This work is notable in part because it is one of the first to examine the impact of loss of HA synthesis in an inflammatory disease. PubMedCrossRef

30.

Bollyky PL, Falk BA, Long SA, Preisinger A, Braun KR, Wu RP, et al. CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-β. J Immunol. 2009;183:2232–41.PubMedCrossRef

31.

Liang J, Jiang D, Griffith J, Yu S, Fan J, Zhao X, et al. CD44 is a negative regulator of acute pulmonary inflammation and lipopolysaccharide-TLR signaling in mouse macrophages. J Immunol. 2007;178:2469–75.PubMed

32.

van der Windt GJ, Hoogendijk AJ, de Vos AF, Kerver ME, Florquin S, van der Poll T. The role of CD44 in the acute and resolution phase of the host response during pneumococcal pneumonia. Lab Invest. 2011;91:588–97.

33.

Schmits R, Filmus J, Gerwin N, Senaldi G, Kiefer F, Kundig T, et al. CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood. 1997;90:2217–33.PubMed

34.

Kimura K, Nagaki M, Kakimi K, Saio M, Saeki T, Okuda Y, et al. Critical role of CD44 in hepatotoxin-mediated liver injury. J Hepatol. 2008;48:952–61.PubMedCrossRef

35.

Chen D, McKallip RJ, Zeytun A, Do Y, Lombard C, Robertson JL, et al. CD44-deficient mice exhibit enhanced hepatitis after concanavalin A injection: evidence for involvement of CD44 in activation-induced cell death. J Immunol. 2001;166:5889–97.PubMed

36.

Huebener P, Abou-Khamis T, Zymek P, Bujak M, Ying X, Chatila K, et al. CD44 is critically involved in infarct healing by regulating the inflammatory and fibrotic response. J Immunol. 2008;180:2625–33.PubMed

37.

Mylona E, Jones KA, Mills ST, Pavlath GK. CD44 regulates myoblast migration and differentiation. J Cell Physiol. 2006;209:314–21.PubMedCrossRef

38.

• Wolny PM, Banerji S, Gounou C, Brisson AR, Day AJ, Jackson DG, et al. Analysis of CD44-hyaluronan interactions in an artificial membrane system: insights into the distinct binding properties of high and low molecular weight hyaluronan. J Biol Chem. 2010;285:30170–80. This is an excellent study of the mechanisms underlying the binding interactions between CD44 and LMW-HA and HMW-HA. PubMedCrossRef

39.

Bollyky PL, Falk BA, Wu RP, Buckner JH, Wight TN, Nepom GT. Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4 + CD25+ regulatory T cells. J Leukoc Biol. 2009;86:567–72.PubMedCrossRef

40.

Bollyky PL, Wu RP, Falk BA, Lord JD, Long SA, Preisinger A, et al. ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. Proc Natl Acad Sci U S A. 2011;108:7938–43.PubMedCrossRef

41.

Peng ST, Su CH, Kuo CC, Shaw CF, Wang HS. CD44 crosslinking-mediated matrix metalloproteinase-9 relocation in breast tumor cells leads to enhanced metastasis. Int J Oncol. 2007;31:1119–26.PubMed

42.

Oertli B, Fan X, Wuthrich RP. Characterization of CD44-mediated hyaluronan binding by renal tubular epithelial cells. Nephrol Dial Transplant. 1998;13:271–8.PubMedCrossRef

43.

Fujii Y, Fujii K, Nakano K, Tanaka Y. Crosslinking of CD44 on human osteoblastic cells upregulates ICAM-1 and VCAM-1. FEBS Lett. 2003;539:45–50.PubMedCrossRef

44.

Gottschalk RA, Corse E, Allison JP. TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J Exp Med. 2010;207:1701–11.PubMedCrossRef

45.

Turner MS, Kane LP, Morel PA. Dominant role of antigen dose in CD4 + Foxp3+ regulatory T cell induction and expansion. J Immunol. 2009;183:4895–903.PubMedCrossRef

46.

Long SA, Rieck M, Tatum M, Bollyky PL, Wu RP, Muller I, Ho JC, Shilling HG, Buckner JH. Low-dose antigen promotes induction of FOXP3 in human CD4+ T Cells. J Immunol. 2011.

47.

Roncarolo MG, Levings MK, Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med. 2001;193:F5–9.PubMedCrossRef

48.

Bollyky PL, Evanko SP, Wu RP, Potter-Perigo S, Long SA, Kinsella B, et al. Th1 cytokines promote T-cell binding to antigen-presenting cells via enhanced hyaluronan production and accumulation at the immune synapse. Cell Mol Immunol. 2010;7:211–20.PubMedCrossRef

49.

Acharya PS, Majumdar S, Jacob M, Hayden J, Mrass P, Weninger W, Assoian RK, Pure E. Fibroblast migration is mediated by CD44-dependent TGF β activation. J Cell Sci. 2008;121:1393–402.PubMedCrossRef

50.

David-Raoudi M, Tranchepain F, Deschrevel B, Vincent JC, Bogdanowicz P, Boumediene K, et al. Differential effects of hyaluronan and its fragments on fibroblasts: relation to wound healing. Wound Repair Regen. 2008;16:274–87.PubMedCrossRef

51.

Kawana H, Karaki H, Higashi M, Miyazaki M, Hilberg F, Kitagawa M, et al. CD44 suppresses TLR-mediated inflammation. J Immunol. 2008;180:4235–45.PubMed

52.

Day AJ, de la Motte CA. Hyaluronan cross-linking: a protective mechanism in inflammation? Trends Immunol. 2005;26:637–43.PubMedCrossRef

53.

Mio K, Stern R. Inhibitors of the hyaluronidases. Matrix Biol. 2002;21:31–7.PubMedCrossRef

54.

Kvezereli M, Michie SA, Yu T, Creusot RJ, Fontaine MJ. TSG-6 protein expression in the pancreatic islets of NOD mice. J Mol Histol. 2008;39:585–93.PubMedCrossRef

55.

Bardos T, Kamath RV, Mikecz K, Glant TT. Anti-inflammatory and chondroprotective effect of TSG-6 (tumor necrosis factor-alpha-stimulated gene-6) in murine models of experimental arthritis. Am J Pathol. 2001;159:1711–21.PubMedCrossRef

56.

Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol. 2002;14:617–23.PubMedCrossRef

57.

Evanko SP, Potter-Perigo S, Bollyky PL, Nepom GT, Wight TN. Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biol. 2012;31:90–100.

58.

Sainio A, Jokela T, Tammi MI, Jarvelainen H. Hyperglycemic conditions modulate connective tissue reorganization by human vascular smooth muscle cells through stimulation of hyaluronan synthesis. Glycobiology. 2010;20:1117–26.PubMedCrossRef

59.

Deguine V, Menasche M, Ferrari P, Fraisse L, Pouliquen Y, Robert L. Free radical depolymerization of hyaluronan by Maillard reaction products: role in liquefaction of aging vitreous. Int J Biol Macromol. 1998;22:17–22.PubMedCrossRef

60.

Wheeler-Jones CP, Farrar CE, Pitsillides AA. Targeting hyaluronan of the endothelial glycocalyx for therapeutic intervention. Curr Opin Investig Drugs. 2010;11:997–1006.PubMed

61.

Sakaguchi S, Setoguchi R, Yagi H, Nomura T. Naturally arising Foxp3-expressing CD25 + CD4+ regulatory T cells in self-tolerance and autoimmune disease. Curr Top Microbiol Immunol. 2006;305:51–66.PubMedCrossRef

62.

• Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol. 2009;155:173–81. This study demonstrates some of the challenges and the potential of examining insulitis in human cadaveric specimens. Similar studies examining the ECM and other components of the islet inflammatory milieu are underway. PubMedCrossRef

63.

Badami E, Sorini C, Coccia M, Usuelli V, Molteni L, Bolla AM, et al. Defective differentiation of regulatory FoxP3+ T cells by small-intestinal dendritic cells in patients with type 1 diabetes. Diabetes. 2011;60:2120–4.PubMedCrossRef

64.

Herrath J, Muller M, Amoudruz P, Janson P, Michaelsson J, Larsson PT, et al. The inflammatory milieu in the rheumatic joint reduces regulatory T-cell function. Eur J Immunol. 2011;41:2279–90.PubMedCrossRef

65.

• Wesley JD, Sather BD, Perdue NR, Ziegler SF, Campbell DJ. Cellular requirements for diabetes induction in DO11.10xRIPmOVA mice. J Immunol. 2010;185:4760–8. This study demonstrates the presence of Foxp3+ regulatory T-cells in autoimmune insulitis and shows that these Treg function well ex vivo, implicating a role for the tissue environment in their evident dysfunction in vivo. PubMedCrossRef

66.

Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008;28:687–97.PubMedCrossRef

67.

Long SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, Zhang S, et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes. 2010;59:407–15.PubMedCrossRef

68.

Vukmanovic-Stejic M, Zhang Y, Akbar AN, Macallan DC. Measurement of proliferation and disappearance of regulatory T cells in human studies using deuterium-labeled glucose. Methods Mol Biol. 2011;707:243–61.PubMedCrossRef

69.

• Oberg HH, Ly TT, Ussat S, Meyer T, Kabelitz D, Wesch D. Differential but direct abolishment of human regulatory T cell suppressive capacity by various TLR2 ligands. J Immunol. 2010;184:4733–40. This study and others reporting the same finding with human Treg offers a possible mechanism for how sterile injury could lead to Treg dysfunction. PubMedCrossRef

70.

Firan M, Dhillon S, Estess P, Siegelman MH. Suppressor activity and potency among regulatory T cells is discriminated by functionally active CD44. Blood. 2006;107:619–27.PubMedCrossRef

71.

Bollyky PL, Lord JD, Masewicz SA, Evanko SP, Buckner JH, Wight TN, et al. Cutting edge: high molecular weight hyaluronan promotes the suppressive effects of CD4 + CD25+ regulatory T cells. J Immunol. 2007;179:744–7.PubMed

72.

Liu T, Soong L, Liu G, Konig R, Chopra AK. CD44 expression positively correlates with Foxp3 expression and suppressive function of CD4+ Treg cells. Biol Direct. 2009;4:40.PubMedCrossRef

73.

Asari A, Kanemitsu T, Kurihara H. Oral administration of high molecular weight hyaluronan (900 kDa) controls immune system via Toll-like receptor 4 in the intestinal epithelium. J Biol Chem. 2010;285:24751–8.PubMedCrossRef

74.

Huang TL, Hsu HC, Yang KC, Lin FH. Hyaluronan up-regulates IL-10 expression in fibroblast-like synoviocytes from patients with tibia plateau fracture. J Orthop Res. 2011;29:495–500.PubMedCrossRef

75.

Larkin J, Renukaradhya GJ, Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR. CD44 differentially activates mouse NK T cells and conventional T cells. J Immunol. 2006;177:268–79.PubMed

76.

Vernon RB, Preisinger A, Gooden MD, D'Amico LA, Yue BB, Bollyky PL, et al. Reversal of diabetes in mice with a bioengineered islet implant incorporating a Type I collagen hydrogel and sustained release of vascular endothelial growth factor. Cell Transplant. 2012. doi:10.3727/096368911X636786.

77.

Parnaud G, Hammar E, Ribaux P, Donath MY, Berney T, Halban PA. Signaling pathways implicated in the stimulation of β-cell proliferation by extracellular matrix. Mol Endocrinol. 2009;23:1264–71.PubMedCrossRef

78.

• Stendahl JC, Kaufman DB, Stupp SI. Extracellular matrix in pancreatic islets: relevance to scaffold design and transplantation. Cell Transplant. 2009;18:1–12. This review is a good introduction to what is known about the ECM in healthy islets. PubMedCrossRef

79.

Cheng JY, Raghunath M, Whitelock J, Poole-Warren L. Matrix components and scaffolds for sustained islet function. Tissue Eng B Rev. 2011;17:235–47.CrossRef

80.

Kaido T, Yebra M, Cirulli V, Rhodes C, Diaferia G, Montgomery AM. Impact of defined matrix interactions on insulin production by cultured human β-cells: effect on insulin content, secretion, and gene transcription. Diabetes. 2006;55:2723–9.PubMedCrossRef

81.

Wang RN, Rosenberg L. Maintenance of β-cell function and survival following islet isolation requires re-establishment of the islet-matrix relationship. J Endocrinol. 1999;163:181–90.PubMedCrossRef

82.

Van Deijnen JH, van Suylichem PT, Wolters GH, van Schilfgaarde R. Distribution of collagens type I, type III and type V in the pancreas of rat, dog, pig and man. Cell Tissue Res. 1994;277:115–21.PubMedCrossRef

83.

Kragl M, Lammert E. Basement membrane in pancreatic islet function. Adv Exp Med Biol. 2010;654:217–34.PubMedCrossRef

84.

Irving-Rodgers HF, Ziolkowski AF, Parish CR, Sado Y, Ninomiya Y, Simeonovic CJ, et al. Molecular composition of the peri-islet basement membrane in NOD mice: a barrier against destructive insulitis. Diabetologia. 2008;51:1680–8.PubMedCrossRef

85.

Daoud J, Petropavlovskaia M, Rosenberg L, Tabrizian M. The effect of extracellular matrix components on the preservation of human islet function in vitro. Biomaterials. 2010;31:1676–82.PubMedCrossRef

86.

Jalili RB, Moeen RA, Hosseini-Tabatabaei A, Ao Z, Warnock GL, Ghahary A. Fibroblast populated collagen matrix promotes islet survival and reduces the number of islets required for diabetes reversal. J Cell Physiol. 2011;226:1813–9.PubMedCrossRef

87.

Takahashi I, Noguchi N, Nata K, Yamada S, Kaneiwa T, Mizumoto S, et al. Important role of heparan sulfate in postnatal islet growth and insulin secretion. Biochem Biophys Res Commun. 2009;383:113–8.PubMedCrossRef

88.

• Ziolkowski AF, Popp SK, Freeman C, Parish CR, Simeonovic CJ. Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes. J Clin Invest. 2012;122:132–41. This is a well done study that raising intriguing possibilities regarding the rolw of ECM in islet homeostasis. PubMedCrossRef

89.

Otonkoski T, Banerjee M, Korsgren O, Thornell LE, Virtanen I. Unique basement membrane structure of human pancreatic islets: implications for β-cell growth and differentiation. Diabetes Obes Metab. 2008;10 Suppl 4:119–27.PubMedCrossRef

90.

Weiss L, Slavin S, Reich S, Cohen P, Shuster S, Stern R, et al. Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody. Proc Natl Acad Sci U S A. 2000;97:285–90.PubMedCrossRef

91.

Midwood KS, Williams LV, Schwarzbauer JE. Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol. 2004;36:1031–7.PubMedCrossRef

92.

Scanzello CR, Plaas A, Crow MK. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound? Curr Opin Rheumatol. 2008;20(5):565–72.

93.

Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110:159–73.PubMedCrossRef

94.

Debussche X, Lormeau B, Boitard C, Toublanc M, Assan R. Course of pancreatic β-cell destruction in prediabetic NOD mice: a histomorphometric evaluation. Diabete Metab. 1994;20:282–90.PubMed

95.

Calafiore R, Pietropaolo M, Basta G, Falorni A, Picchio ML, Brunetti P. Pancreatic β-cell destruction in non-obese diabetic mice. Metabolism. 1993;42:854–9.PubMedCrossRef

96.

Reddy S, Bradley J. Immunohistochemical demonstration of nitrotyrosine, a biomarker of oxidative stress, in islet cells of the NOD mouse. Ann N Y Acad Sci. 2004;1037:199–202.PubMedCrossRef

97.

Estella E, McKenzie MD, Catterall T, Sutton VR, Bird PI, Trapani JA, et al. Granzyme B-mediated death of pancreatic β-cells requires the proapoptotic BH3-only molecule bid. Diabetes. 2006;55:2212–9.PubMedCrossRef

98.

Papaccio G, Linn T, Federlin K, Volkman A, Esposito V, Mezzogiorno V. Further morphological and biochemical observations on early low dose streptozocin diabetes in mice. Pancreas. 1991;6:659–67.PubMedCrossRef

99.

Rakus JF, Mahal LK. New technologies for glycomic analysis: toward a systematic understanding of the glycome. Annu Rev Anal Chem (Palo Alto Calif). 2011;4:367–92.CrossRef

100.

•• Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, Hynes RO. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics. 2012;11:M111. These authors outline a novel and comprehensive approach to characterization of the ECM in different tissues that will be useful in T1D studies. PubMed

Title: The Role of Hyaluronan and the Extracellular Matrix in Islet Inflammation and Immune Regulation
Authors: Paul L. Bollyky
Marika Bogdani
Jennifer B. Bollyky
Rebecca L. Hull
Thomas N. Wight
Publication date: 01-10-2012
Publisher: Current Science Inc.
Published in: Current Diabetes Reports / Issue 5/2012
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-012-0297-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2012

Adipose Tissue, Hormones, and Treatment of Type 1 Diabetes

Possible Role of GLP-1 and Its Agonists in the Treatment of Type 1 Diabetes Mellitus

No Islets Left Behind: Islet Autotransplantation for Surgery-Induced Diabetes

Erratum to: Understanding Pancreas Development for β-Cell Repair and Replacement Therapies

Autologous Regulatory T Cells for the Treatment of Type 1 Diabetes

Transplantation of the Pancreas

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials